About Taste receptor type 2 member 43
Taste receptor type 2 member 43 (TAS2R43) is a protein
from Homo sapiens identified by UniProt accession
P59537, 309 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | Taste receptor type 2 member 43 |
|---|
| UniProt accession | P59537 |
|---|
| Gene | TAS2R43 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 309 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (22)
Diseases linked to this target (Open Targets).
- ovarian cancer · score 0.18
- breast adenocarcinoma · score 0.16
- medulloblastoma · score 0.13
- head and neck squamous cell carcinoma · score 0.13
- gastric adenocarcinoma · score 0.10
- sensory perception of bitter taste · score 0.06
- squamous cell carcinoma · score 0.05
- actinic keratosis · score 0.05
- Obesity · score 0.05
- blood protein measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P59537-F1 | alphafold | PREDICTED | 86.72 | — |
Amino-acid sequence (309 residues)
MITFLPIIFS SLVVVTFVIG NFANGFIALV NSIEWFKRQK ISFADQILTA LAVSRVGLLW VLLLNWYSTV LNPAFNSVEV RTTAYNIWAV INHFSNWLAT TLSIFYLLKI ANFSNFIFLH LKRRVKSVIL VMLLGPLLFL ACHLFVINMN EIVRTKEFEG NMTWKIKLKS AMYFSNMTVT MVANLVPFTL TLLSFMLLIC SLCKHLKKMQ LHGKGSQDPS TKVHIKALQT VISFLLLCAI YFLSIMISVW SFGSLENKPV FMFCKAIRFS YPSIHPFILI WGNKKLKQTF LSVFWQMRYW VKGEKTSSP
Explore Taste receptor type 2 member 43 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets